Medway Community Healthcare Medway NHS Trust Foundation Trust
Medway Clinical Commissioning Group Swale Clinical Commissioning Group
Online Formulary

13.7.1. Alopecia

 

Ritlecitinib (Litfulo®)

This High-Cost Drug has been approved for the following indications: - as an option for treating severe alopecia areata in people 12 years and over as per NICE TA958.   
(Ritlecitinib is only recommended if the company provides it according to the commercial arrangement.)
For more information and NICE Guidance
Click Here		 Ritlecitinib for treating severe alopecia areata in people 12 years and over NICE TA958
ICB commissioned - approval via Blueteq supplied via Homecare
  • First Line Choice
  • On Formulary
  • Specialist Initiation Only
  • Hospital Only
  • KMPT Initiation Only
  •